EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

DWN12088, A Prolyl-tRNA Synthetase Inhibitor, Alleviates Hepatic Injury in Nonalcoholic Steatohepatitis

Dong-Keon Lee, Su Ho Jo, Eun Soo Lee, Kyung Bong Ha, Na Won Park, Deok-Hoon Kong, Sang-In Park, Joon Seok Park, Choon Hee Chung

Diabetes & Metabolism Journal · 2024

DOI: 10.4093/dmj.2022.0367 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Diabetes & Metabolism Journal, 2024. Verfasst von Dong-Keon Lee und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Internal Medicine and Research Institute of Metabolism and Inflammation, Yonsei University Wonju College of Medicine, Wonju, Korea. Hauptthemen laut MEDLINE: Non-alcoholic Fatty Liver Disease, Amino Acyl-tRNA Synthetases. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 43 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: National Research Foundation of Korea, Ministry of Science, ICT and Future Planning, Ministry of Education.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Nonalcoholic steatohepatitis (NASH) is a liver disease caused by obesity that leads to hepatic lipoapoptosis, resulting in fibrosis and cirrhosis. However, the mechanism underlying NASH is largely unknown, and there is currently no effective therapeutic agent against it. DWN12088, an agent used for treating idiopathic pulmonary fibrosis, is a selective prolyl-tRNA synthetase (PRS) inhibitor that suppresses the synthesis of collagen. However, the mechanism underlying the hepatoprotective effect of DWN12088 is not clear. Therefore, we investigated the role of DWN12088 in NASH progression.

Methods

Mice were fed a chow diet or methionine-choline deficient (MCD)-diet, which was administered with DWN12088 or saline by oral gavage for 6 weeks. The effects of DWN12088 on NASH were evaluated by pathophysiological examinations, such as real-time quantitative reverse transcription polymerase chain reaction, immunoblotting, biochemical analysis, and immunohistochemistry. Molecular and cellular mechanisms of hepatic injury were assessed by in vitro cell culture.

Results

DWN12088 attenuated palmitic acid (PA)-induced lipid accumulation and lipoapoptosis by downregulating the Rho-kinase (ROCK)/AMP-activated protein kinase (AMPK)/sterol regulatory element-binding protein-1c (SREBP-1c) and protein kinase R-like endoplasmic reticulum kinase (PERK)/α subunit of eukaryotic initiation factor 2 (eIF2α)/activating transcription factor 4 (ATF4)/C/EBP-homologous protein (CHOP) signaling cascades. PA increased but DWN12088 inhibited the phosphorylation of nuclear factor-κB (NF-κB) p65 (Ser536, Ser276) and the expression of proinflammatory genes. Moreover, the DWN12088 inhibited transforming growth factor β (TGFβ)-induced pro-fibrotic gene expression by suppressing TGFβ receptor 1 (TGFβR1)/Smad2/3 and TGFβR1/glutamyl-prolyl-tRNA synthetase (EPRS)/signal transducer and activator of transcription 6 (STAT6) axis signaling. In the case of MCD-diet-induced NASH, DWN12088 reduced hepatic steatosis, inflammation, and lipoapoptosis and prevented the progression of fibrosis.

Conclusion

Our findings provide new insights about DWN12088, namely that it plays an important role in the overall improvement of NASH. Hence, DWN12088 shows great potential to be developed as a new integrated therapeutic agent for NASH.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Non-alcoholic Fatty Liver DiseaseAmino Acyl-tRNA SynthetasesMiceAnimalsLiver CirrhosisFibrosisCholineMethionineTransforming Growth Factor beta

Stichwörter der Autor:innen

Idiopathic pulmonary fibrosisInflammationNon-alcoholic fatty liver diseasePalmitic acidProlyl tRNA synthetaseTransforming growth factor beta

Substanzen

CholineMethionineTransforming Growth Factor betaAmino Acyl-tRNA Synthetases

Autor:innen und Institutionen

  • Department of Internal Medicine and Research Institute of Metabolism and Inflammation, Yonsei University Wonju College of Medicine, Wonju, Korea.
  • Division of Research Program, Scripps Korea Antibody Institute, Chuncheon, Korea.
  • Drug Discovery Center, Daewoong Pharmaceutical Co. Ltd., Seoul, Korea.

Förderung

  • National Research Foundation of Korea
  • Ministry of Science, ICT and Future Planning
  • Ministry of Education
  • Ministry of Science and ICT

Zitieren

APA

Lee, D. K., Jo, S. H., Lee, E. S., Ha, K. B., Park, N. W., Kong, D. H., Park, S. I., Park, J. S., & Chung, C. H. (2024). DWN12088, A Prolyl-tRNA Synthetase Inhibitor, Alleviates Hepatic Injury in Nonalcoholic Steatohepatitis. Diabetes & Metabolism Journal. https://doi.org/10.4093/dmj.2022.0367

Vancouver

Lee DK, Jo SH, Lee ES, Ha KB, Park NW, Kong DH, et al. DWN12088, A Prolyl-tRNA Synthetase Inhibitor, Alleviates Hepatic Injury in Nonalcoholic Steatohepatitis. Diabetes & Metabolism Journal. 2024. doi:10.4093/dmj.2022.0367

BibTeX
@article{Lee2024,
  author = {Lee, Dong-Keon and Jo, Su Ho and Lee, Eun Soo and Ha, Kyung Bong and Park, Na Won and Kong, Deok-Hoon and Park, Sang-In and Park, Joon Seok and Chung, Choon Hee},
  title = {DWN12088, A Prolyl-tRNA Synthetase Inhibitor, Alleviates Hepatic Injury in Nonalcoholic Steatohepatitis},
  journal = {Diabetes & Metabolism Journal},
  year = {2024},
  doi = {10.4093/dmj.2022.0367}
}
Kostenlos starten →